Juan W. Valle, MB ChB MSc FRCP’s Post

Gene therapies are rapidly changing concepts about the treatment of previously thought to be intractable diseases. Treatment of eye disorders is showing promise. Dial in and listen to an expert panel discuss the state-of-the-art in this space.

💫 #ONCOnews 💫 🌟 Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma 👉 The trial results suggest that trends for enhanced survival in subsets of patients may provide insights for designing subsequent trials with the next generation of more selective, brain-penetrant PARP inhibitors. 🔗 https://buff.ly/48s7TGt #OncEd #OncoAlert

⏰ Coming up next at #ASCO24: 👉 Robert Motzer, MD, and colleagues are presenting data from the final anlaysis of the #Javelin #Renal 101 trial on the efficacy of #Avelumab plus #Axitinib. 🧠 Read More:

Inhibikase is working to advance Parkinson’s treatments through our development of small-molecule kinase inhibitors. Our 201 clinical trial exploring whether risvodetinib (IkT-148009), can slow or halt progression of Parkinson’s disease is currently enrolling. Learn more this #ParkinsonsAwarenessMonth: https://bit.ly/3qhye8l

🔊 We spoke with Sia Daneshmand, M.D. on the biggest developments and key highlights in #bladdercancer from the #LUGPA 2024 Annual Meeting. 📺 Learn about the recent approval of ANKTIVA, data from the SunRISe-1 study on the TAR-200 drug delivery system, and more: https://buff.ly/3V3ZUd4

🌍 Collaborating for Progress in Hepatitis B Research | Global Insights from Dr. Ning & Prof. Kennedy 🌍 In a recent discussion, Dr. Qin Ning and Professor Patrick T.F. Kennedy delved into the complexities of managing chronic hepatitis B. Both experts emphasized the significance of international collaboration and research exchange to advance diagnostics, therapeutics, and ultimately, functional cure efforts. By combining insights from different populations, including Chinese and European patients, this collaborative approach aims to deepen the understanding of the disease and tailor treatments to individual patients. 🤝🧬 #HepatitisResearch #GlobalCollaboration #MedicalInnovation

Future treatment for metastatic #ColorectalCancer (#mCRC) after progression could lie with molecularly targeted therapies and several promising combinations are currently in development, according to Sara Lonardi who commented on preliminary findings from trials presented at #ESMO24. EGFR inhibitor rechallenge with cetuximab plus irinotecan and the addition of amivantamab to FOLFOX or FOLFIRI produced encouraging data with no unexpected side effects. The RAMTAS/IKF643 trial assessed ramucirumab plus standard chemotherapy with improved PFS but not OS. The full article is available on the #ESMODailyReporter 📌https://ow.ly/oahN50TnIM5

Early detection of EBV-positive PTLD can make a life-saving difference for transplant patients. Get up-to-speed on best practices and emerging therapies in this Hematology Dialogues course, recorded at #SOHO2024, and earn CE credit for free 👉 mli.link/ebv

My second PhD paper is officially in press and has been selected as the Editor's Choice for the month in Osteoarthritis and Cartilage Journal! A big thank you to the editors for highlighting our research on the structural, mechanical, and transcriptional changes in the synovium of dogs with naturally occurring cruciate ligament tears, and how these insights could guide targeted interventions. Check out the paper below to explore the intriguing similarities between synovial inflammation in our canine companions and humans with cruciate tears ⬇️

The price of cancer treatment can be financially straining for patients and their families. Rena M. Conti of Boston University and coauthors describe recent trends in drug prices and assess the impact of competition among 185 anticancer medicines. Read the full article here: https://lnkd.in/e32HehPu